NCT07389642

Brain Oligometastasis in NSCLC

Management of Patients With Brain-onset Oligometastatic Non-small-cell Lung Cancer (NSCLC)

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 46 (actual)
• Sponsor: University Hospital, Bordeaux · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: —

Summary

75-80% of NSCLC are diagnosed at the metastatic stage. Among the most frequent sites are brain metastases. The management of patients with exclusive limited brain involvement is not standardized. The question is therefore which therapeutic strategy is optimal in such disease presentation. We will analyze the impact of different therapeutic strategies on patients treated at Bordeaux University Hospital and the Bergonié Institute

Detailed description

75-80% of NSCLC are diagnosed at the metastatic stage. Among the most frequent sites are brain metastases. The management of patients with exclusive limited brain involvement is not standardized. The question is therefore which therapeutic strategy is optimal in terms of disease control: local treatment of the main tumor and brain versus systemic treatment with chemotherapy and immunotherapy. We will analyze the impact of these 2 strategies on patients treated at Bordeaux University Hospital and the Bergonié Institute.

Conditions

• Brain Oligometastatic
• Non-small Cell Lung Cancer

Interventions

Type	Name	Description
OTHER	Standard treatments / multiple strategies	Standard treatments / multiple strategies

Timeline

• Start date: 2025-01-01
• Primary completion: 2026-03-01
• Completion: 2026-03-01
• First posted: 2026-02-05
• Last updated: 2026-02-05

Locations

1 site across 1 country: France